Merus NV

Merus NV, a clinical‐stage immuno‑oncology company headquartered in Utrecht, develops bispecific antibody therapeutics including BIZENGRI and MCLA‑158 for solid tumors, and benefits from collaborations with Lilly, Ono and Betta while operating as a Genmab subsidiary.

Headquarters: United States (USA)

Merus NV Logo
Company Profile
  • Employees: 260
  • HQ: Utrecht
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
MRUS Merus NV
Cap: 6.8B
EQUITY NGM USD NL0011606264 Active
📈
Home Login